中国生化原料药的现状和展望

Development and Prospects of Biochemical Drug

我国生化制药企业有289家,产品品种达700余种(包括原料药和制剂),工业总产值110亿元,出口交货值超过1亿美元。我国能够生产氨基酸类、多肽与蛋白质类、多糖类、酶类、脂类、核酸及其衍生物类等生化原料药,主要出口产品包括肝素、玻璃酸、硫酸软骨素、甲壳质、尿激酶、胰酶、辅酶A和胱氨酸等。中国用于生产生化原料药的生物原料极为丰富,且许多生化原料药在今后相当长时间内还属于资源依赖性产品,我国发展生化原料药应以生物提取和纯化为主要生产方法,同时发展微生物发酵工程和基因重组等现代生物技术。

There are 289 biochemical companies in China with over 700 product varieties (include drug and preparation) , the total production value reached 11 billion yuan and export delivery value exceed 100 million US dollar. Amino acid, polypep-tide and protein, polysaccharide, enzyme, lipid, nucleic acid and its derivatives can be produced in China,at the same time, the main export output includes heparin, hyaluronic acid, chondroitin sulfate, chitin, urokinase, pancreatic enzyme, coenzyme A, cystine and etc. In China, biomaterial is abundant for manufacturing biochemical drug. Because the biochemical drug belongs to resource-dependent-product, main production processes must be developed on the basis of bio-extraction and purification, and also modern biotechnology such as microbial fermentation engineering and genie recombination.